Alcobra Ltd. to Participate in Upcoming Healthcare Conferences

TEL AVIV, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that management will participate in several upcoming investor healthcare conferences.

Stifel Healthcare Conference
Date:Tuesday, November 15
Time:4:30PM EST
Location:The Lotte New York Palace Hotel
Jefferies London Healthcare Conference
Date:Thursday, November 17
Time:09:20AM GMT
Location:Waldorf Hilton, London, United Kingdom
Webcast:http://wsw.com/webcast/jeff100/adhd
28th Annual Piper Jaffray Healthcare Conference
Date:Tuesday, November 29
Time:10:00AM EST
Panel Title: Underdiscovered Neuro-Innovators Panel
Location:The Lotte New York Palace Hotel
Oppenheimer Life Sciences Summit
Date:Tuesday, November 29
Location:The Sofitel New York Hotel

About Alcobra

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX (Metadoxine Extended Release), a proprietary drug candidate to treat cognitive disorders including ADHD and Fragile X Syndrome. For more information, please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Source:Alcobra Ltd.